Other languages Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Real-time Estimate Cboe BZX Other stock markets 12:57:20 01/05/2024 am IST			5-day change	1st Jan Change
60.56 ^USD	-0.76%		+0.20%	-2.87%

25/04	Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	MT
22/04	Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	26/04
Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	23/04
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing	21/03
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	04/03
Vaxcyte Q4 Loss Widens	28/02
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Vaxcyte Insider Sold Shares Worth $357,500, According to a Recent SEC Filing	03/02
Vaxcyte Insider Sold Shares Worth $1,980,900, According to a Recent SEC Filing	01/02
Vaxcyte Insider Sold Shares Worth $270,000, According to a Recent SEC Filing	01/02
Vaxcyte Launches Securities Offering; Shares Fall After Hours	31/01
Sector Update: Health Care Stocks Advance Monday Afternoon	30/01
Vaxcyte Shares Rise After Completion of Enrollment for Phase 1/2 Clinical Study Assessing Vaccine Candidate	29/01
Vaxcyte Completes Enrollment for Phase 1/2 Clinical Study Assessing Pneumococcal Conjugate Vaccine Candidate	29/01
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Aged 50 and Older	29/01
Vaxcyte Insider Sold Shares Worth $958,783, According to a Recent SEC Filing	26/01
Vaxcyte Insider Sold Shares Worth $485,879, According to a Recent SEC Filing	20/01
Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer	17/01
Vaxcyte Shares Drop After Clinical Pipeline Updates	06/01
Vaxcyte Insider Sold Shares Worth $828,915, According to a Recent SEC Filing	05/01
Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise	05/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Other languages

Filters